Patents Assigned to CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
-
Patent number: 9290582Abstract: The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.Type: GrantFiled: May 26, 2011Date of Patent: March 22, 2016Assignees: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD., SICHUAN UNIVERSITYInventors: Li Yang, Yuquan Wei
-
Patent number: 9096601Abstract: Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).Type: GrantFiled: December 23, 2010Date of Patent: August 4, 2015Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Sichuan UniversityInventors: Shengyong Yang, Yuquan Wei
-
Patent number: 9012628Abstract: Provided is a crystalline form E of ertapenem sodium. Further provided is a method for preparing a crystalline form E of ertapenem sodium, characterized by using an aqueous ertapenem sodium solution at a low concentration as a raw material. The crystalline form E can be easily filtered and dried, the properties in the drying process are stable, and the purity of the crystal is high and can be up to 98.5% or higher.Type: GrantFiled: December 22, 2011Date of Patent: April 21, 2015Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.Inventors: Ying Shi, Kun Li, Xuebin Zhao, Zan Xie, Yuxiu Ma, Jian Lv, Ming Jia
-
Patent number: 8871253Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether ?-cyclodextrin, sulfobutyl ether ?-cyclodextrin, or sulfobutyl ether ?-cyclodextrin.Type: GrantFiled: October 26, 2010Date of Patent: October 28, 2014Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.Inventors: Chunlei Li, Lan Zhang, Caixia Wang, Li Zhang, Dongmin Shen, Yanhui Li, Xian Xiu, Min Liang, Yongfeng Li
-
Patent number: 8772312Abstract: This application relates to a compound of Formula ! (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an antagonist of receptor CRTH2, as well as a process for its preparation and intermediates therefor.Type: GrantFiled: October 9, 2008Date of Patent: July 8, 2014Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Centaurus Biopharma Co., Ltd.Inventor: Wei W. Yuan
-
Patent number: 8728518Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.Type: GrantFiled: August 26, 2005Date of Patent: May 20, 2014Assignee: CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., LtdInventors: Zhentao Liu, Liying Yang, Hanyu Yang, Yuqing Gao, Dongmin Shen, Wenmin Guo, Xiaolong Feng, Jia Zheng
-
Patent number: 8680097Abstract: The invention discloses benzothiophene alkanol piperazine derivatives and their use as antidepressants. The invention discloses the said benzothiophene alkanol piperazine derivative having triple inhibition effect on the reuptake of 5-HT, NA and DA. Compared with clinical used antidepressants so far having single target, e.g. desipramine and fluoxetine, and clinical used antidepressants so far having double targets, e.g venlafaxine and duloxetine, the said benzothiophene alkanol piperazine derivatives of the present invention may have a broader indication range and less toxic and side effects to nervous system. The benzothiophene alkanol piperazine derivatives are the compounds with the following formula or their pharmaceutically acceptable salts, wherein Ar1, R1-R4, X, Y, m and n have the same definition as defined in claim 1.Type: GrantFiled: June 30, 2009Date of Patent: March 25, 2014Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Shanghai Institute of Pharmaceutical IndustryInventors: Jianqi Li, Kai Gao, Na Lv
-
Patent number: 8609137Abstract: The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in a weight ratio of about 1:0˜10. The capsule wall material is composed of a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2˜0.4:0.8˜1.3. The soft capsule of butylphthalide described in the present invention can mask the strong and special flavor of butylphthalide, and overcome the difficulties associated with formulating oily active ingredient into other oral formulation. The disintegration time of the soft capsule satisfies the requirement of Pharmacopoeia of P.R. China.Type: GrantFiled: April 22, 2011Date of Patent: December 17, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC NBP Pharmaceutical Co., Ltd.Inventors: Jianqing Li, Min Bai, Wenmin Guo, Surui Chen, Liyun Liu, Guirong Zhou
-
Patent number: 8598225Abstract: The present invention discloses the use of L-butylphthalide of formula (I) in the manufacture of medicaments for the prevention and treatment of cerebral infarct, especially induced by focal cerebral ischemia.Type: GrantFiled: October 20, 2010Date of Patent: December 3, 2013Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.Inventors: Yipu Feng, Xiaoliang Wang, Jinghua Yang, Ying Peng
-
Publication number: 20130281427Abstract: Provided is a crystalline form E of ertapenem sodium. Further provided is a method for preparing a crystalline form E of ertapenem sodium, characterized by using an aqueous ertapenem sodium solution at a low concentration as a raw material. The crystalline form E can be easily filtered and dried, the properties in the drying process are stable, and the purity of the crystal is high and can be up to 98.5% or higher.Type: ApplicationFiled: December 22, 2011Publication date: October 24, 2013Applicant: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.Inventors: Ying Shi, Kun Li, Xuebin Zhao, Zan Xie, Yuxiu Ma, Jian Lv, Ming Jia
-
Publication number: 20130089549Abstract: The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.Type: ApplicationFiled: May 26, 2011Publication date: April 11, 2013Applicants: SICHUAN UNIVERSITY, CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.Inventors: Li Yang, Yuquan Wei
-
Patent number: 8399511Abstract: Two crystalline forms of pinocembrin of formula (I): ? and ?, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.Type: GrantFiled: November 13, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Guanhua Du, Yang Lv, Song Wu, Ke Wang, Ying Chang, Zhihong Yang, Yuanfeng Tong, Mei Gao
-
Method for resolution of a mixture of pinocembrin optical isomers, especially a pinocembrin racemate
Patent number: 8399691Abstract: The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.Type: GrantFiled: November 7, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Song Wu, Guanhua Du, Yue Yuan, Qingyun Yang, Mei Gao, Yan Qi, Yuanfeng Tong, Yuehua Wang -
Publication number: 20120095209Abstract: Intermediates of Ertapenem of formula 2a wherein Np represents (I) or (II), and P1 and P2 represent carboxyl protecting groups, and their preparation methods. Compound 2a prepared by the present methods in solid form is amorphous. The present invention also relates to a composition comprising at least 95% of the intermediate of Ertapenem of formula 2a.Type: ApplicationFiled: April 30, 2010Publication date: April 19, 2012Applicant: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.Inventors: Ying Shi, Kun Li, Zan Xie, Xuebin Zhao, Jian Lv, Xiuqin Yu
-
Publication number: 20110118263Abstract: The invention discloses benzothiophene alkanol piperazine derivatives and their use as antidepressants. The invention discloses the said benzothiophene alkanol piperazine derivative having triple inhibition effect on the reuptake of 5-HT, NA and DA. Compared with clinical used antidepressants so far having single target, e.g. desipramine and fluoxetine, and clinical used antidepressants so far having double targets, e.g venlafaxine and duloxetine, the said benzothiophene alkanol piperazine derivatives of the present invention may have a broader indication range and less toxic and side effects to nervous system. The benzothiophene alkanol piperazine derivatives are the compounds with the following formula or their pharmaceutically acceptable salts, wherein Ar1, R1-R4, X, Y, m and n have the same definition as defined in claim 1.Type: ApplicationFiled: June 30, 2009Publication date: May 19, 2011Applicant: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.Inventors: Jianqi Li, Kai Gao, Na Lv